Herpes Zoster Vaccines.
herpes zoster
live attenuated Oka varicella-zoster vaccine
recombinant zoster vaccine
zoster vaccine
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
30 09 2021
30 09 2021
Historique:
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
11
3
2022
Statut:
ppublish
Résumé
Herpes zoster (HZ) affects approximately 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age. The most common, debilitating complication of HZ is the chronic neuropathic pain of postherpetic neuralgia (PHN). Two herpes zoster vaccines, a live-attenuated varicella-zoster virus (VZV) vaccine (zoster vaccine live [ZVL]; ZOSTAVAX [Merck]) and an adjuvanted VZV glycoprotein E (gE) subunit vaccine (recombinant zoster vaccine [RZV]; SHINGRIX [GlaxoSmithKline]) are licensed for the prevention of HZ and PHN in healthy older adults. The safety and efficacy of both vaccines has been demonstrated in clinical trials in immunocompetent adults and in selected immunocompromised persons and persons with immune-mediated diseases. Numerous real-world effectiveness studies have confirmed the safety and effectiveness of both ZVL and RZV. Recombinant zoster vaccine (RZV) is more effective for prevention of HZ than ZVL. Recombinant zoster vaccine is nonreplicating and is thus safe in immunocompromised persons. Additional zoster vaccines are in different stages of development. Wider distribution of safe and effective zoster vaccines will improve the health and well being of the rapidly growing population of older adults around the world.
Identifiants
pubmed: 34590136
pii: 6378089
doi: 10.1093/infdis/jiab387
pmc: PMC8482024
doi:
Substances chimiques
Herpes Zoster Vaccine
0
Vaccines, Subunit
0
Vaccines, Synthetic
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
S429-S442Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
N Engl J Med. 2016 Sep 15;375(11):1019-32
pubmed: 27626517
Lancet Infect Dis. 2019 Sep;19(9):988-1000
pubmed: 31399377
N Engl J Med. 2015 May 28;372(22):2087-96
pubmed: 25916341
MMWR Morb Mortal Wkly Rep. 2019 Feb 01;68(4):91-94
pubmed: 30703077
J Infect Dis. 2015 Apr 15;211(8):1279-87
pubmed: 25371534
N Engl J Med. 2005 Jun 2;352(22):2271-84
pubmed: 15930418
Proc R Soc Med. 1965 Jan;58:9-20
pubmed: 14267505
J Pain. 2004 Aug;5(6):344-56
pubmed: 15336639
Clin Infect Dis. 2010 Jul 15;51(2):197-213
pubmed: 20550454
Clin Infect Dis. 2012 Apr;54(7):922-8
pubmed: 22291101
Vaccine. 2017 Dec 19;35(52):7231-7239
pubmed: 29174682
Clin Infect Dis. 2019 Jul 2;69(2):341-344
pubmed: 30496358
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108
pubmed: 29370152
Clin Infect Dis. 2018 Nov 13;67(11):1712-1719
pubmed: 29590326